Evaluation of the therapeutic activity of tulathromycin against swine respiratory disease on farms in Europe.
The clinical efficacy of tulathromycin in the treatment of natural outbreaks of swine respiratory disease (SRD) was evaluated at five European sites. Pigs (1 to 6 months of age) exhibiting clinical signs of SRD were treated intramuscularly with tulathromycin (n = 247) at 2.5 mg/kg on day 0 versus either tiamulin (n = 102) at 15 mg/kg on days 0, 1, and 2 (Germany, the Netherlands, and the United Kingdom) or florfenicol (n = 20) at 15 mg/kg on days 0 and 2 (France). Actinobacillus pleuropneumoniae, Pasteurella multocida, and Mycoplasma hyopneumoniae infections were the most frequently diagnosed pathogens. For both tulathromycin-treated animals and those treated with tiamulin or florfenicol, there were significant (P = .0001) reductions in mean rectal temperature and the severity of abnormal clinical signs on days 2 and 10 compared with day 0. There were no significant differences (P > .05) between treatments in average daily weight gain. Tulathromycin was found to be safe and highly effective in the treatment of natural outbreaks of SRD.
Nanjiani
Ian A
IA
Veterinary Medicine Research and Development, Pfizer Ltd, Sandwich, Kent, UK.
McKelvie
Jo
J
Benchaoui
Hafid A
HA
Godinho
Kevin S
KS
Sherington
John
J
Sunderland
Simon J
SJ
Weatherley
Andrew J
AJ
Rowan
Tim G
TG
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004187:Disaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000662:veterinary; D004224:Diterpenes / Q000008:administration & dosage / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007273:Injections, Intramuscular / Q000662:veterinary; D012766:Pasteurellosis, Pneumonic / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D012720:Severity of Illness Index; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D013839:Thiamphenicol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D018942:Macrolides
D000900:Anti-Bacterial Agents; D004187:Disaccharides; D004224:Diterpenes; D006571:Heterocyclic Compounds; D013839:Thiamphenicol; C035534:florfenicol; C014224:tiamulin; C485204:tulathromycin; D018942:Macrolides